Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

Published:2011-09-21 Issue:6 Volume:80 Page:1156-1165
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Eiki Jun-ichi,Nagata Yasufumi,Futamura Mayumi,Sasaki-Yamamoto Kaori,Iino Tomoharu,Nishimura Teruyuki,Chiba Masato,Ohyama Sumika,Yoshida-Yoshimioto Riki,Fujii Kenji,Hosaka Hideka,Goto-Shimazaki Hiroko,Kadotani Akito,Ohe Tomoyuki,Lin Songnian,Langdon Ronald B.,Berger Joel P.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference36 articles.

1. Involvement of glucokinase translocation in the mechanism by which resorcinol inhibits glycolysis in hepatocytes

2. Garlic Accelerates Red Blood Cell Turnover and Splenic Erythropoietic Gene Expression in Mice: Evidence for Erythropoietin-Independent Erythropoiesis

3. Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

4. Evaluation of a real-time, continuous monitor of glucose concentration in healthy dogs during anesthesia

5. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes;Journal of Diabetes;2024-04-25

2. Glucokinase and glucokinase activator;Life Metabolism;2023-07-13

3. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial;Nature Medicine;2022-05

4. Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator;PLOS ONE;2022-03-21

5. Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132);Journal of Medicinal Chemistry;2022-02-18